Leerink Swann Upgrades Illumina to Buy

By Ryan Adsit

In a report released today, Puneet Souda from Leerink Swann upgraded Illumina (NASDAQ: ILMN) to Buy. The company’s shares closed last Friday at $160.42.

According to TipRanks.com, Souda is ranked #2893 out of 4560 analysts.

Illumina has an analyst consensus of Moderate Buy, with a price target consensus of $175.

The company has a one year high of $186.88 and a one year low of $119.37. Currently, Illumina has an average volume of 1.09M.

Based on the recent corporate insider activity of 109 insiders, corporate insider sentiment is negative on the stock. Most recently, in June 2014, Christian Henry, the EVP & CCO of ILMN sold 437 shares for a total of $74,434.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Illumina, Inc. develops, manufactures and markets integrated systems for the analysis of genetic variation and function. The company provides sequencing and array-based solutions for genetic analysis in addition to selling products, it provide genotyping, NIPT and whole-genome sequencing services. Its customers include leading genomic research centers, academic institutions, government laboratories, hospitals, and reference laboratories as well as pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic, and consumer genomics companies. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.